ATE440615T1 - Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie - Google Patents
Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapieInfo
- Publication number
- ATE440615T1 ATE440615T1 AT02076487T AT02076487T ATE440615T1 AT E440615 T1 ATE440615 T1 AT E440615T1 AT 02076487 T AT02076487 T AT 02076487T AT 02076487 T AT02076487 T AT 02076487T AT E440615 T1 ATE440615 T1 AT E440615T1
- Authority
- AT
- Austria
- Prior art keywords
- methioninase
- chemotherapy
- antimethionine
- antitumor agent
- methionine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97916592A | 1992-11-19 | 1992-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440615T1 true ATE440615T1 (de) | 2009-09-15 |
Family
ID=25526753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94901634T ATE225403T1 (de) | 1992-11-19 | 1993-11-19 | Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie |
| AT02076487T ATE440615T1 (de) | 1992-11-19 | 1993-11-19 | Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94901634T ATE225403T1 (de) | 1992-11-19 | 1993-11-19 | Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5690929A (de) |
| EP (2) | EP1287830B1 (de) |
| JP (1) | JP2930723B2 (de) |
| AT (2) | ATE225403T1 (de) |
| AU (1) | AU687768B2 (de) |
| CA (1) | CA2149776C (de) |
| DE (2) | DE69332357T2 (de) |
| DK (1) | DK0668933T3 (de) |
| ES (1) | ES2184756T3 (de) |
| PT (1) | PT668933E (de) |
| WO (1) | WO1994011535A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6461851B1 (en) | 1992-11-19 | 2002-10-08 | Anticancer, Inc. | High expression modules containing two or more tandem copies of a methioninase encoding sequence |
| US5891704A (en) * | 1992-11-19 | 1999-04-06 | Anticancer, Inc. | Method to produce high levels of methioninase |
| US5861154A (en) * | 1995-10-30 | 1999-01-19 | Shionogi & Co., Ltd. | Recombinant L-methionine γ-lyase |
| GB9617683D0 (en) | 1996-08-23 | 1996-10-02 | Univ Glasgow | Homocysteine desulphurase |
| DE69837005T2 (de) | 1997-03-13 | 2007-11-15 | Anticancer Inc., San Diego | Verfahren zur herstellung von kristallen der l-methionin-gamma-lyase |
| DE69837205T2 (de) * | 1997-08-08 | 2007-11-22 | Anticancer Inc., San Diego | Hochexprimierende module mit zwei oder mehreren tandemkopien einer für methioninase kodierenden sequenz |
| US5885767A (en) * | 1998-05-22 | 1999-03-23 | Biocatalytics, Inc. | Methods and compositions for quantitating L-homocysteine and/or l-methionine in a solution |
| US6524571B1 (en) * | 1998-10-16 | 2003-02-25 | Anticancer, Inc. | Methioninase gene therapy for tumor treatment |
| EP1176968B1 (de) | 1999-05-11 | 2004-11-17 | Anticancer, Inc. | Selen enthaltendes vorstufearzneimittel für krebstherapie |
| AU2001280155A1 (en) | 2000-09-05 | 2002-03-22 | Shionogi And Co., Ltd. | L-methionine gamma-lyase with modified function |
| US20030129262A1 (en) * | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
| US20070207158A1 (en) * | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20110002978A1 (en) | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
| US7264819B2 (en) * | 2003-06-23 | 2007-09-04 | Anticancer, Inc. | Lyase treatment for P. carinii |
| EP1664326A2 (de) * | 2003-07-31 | 2006-06-07 | Anticancer, Inc. | Verwendung von plp mit peg-rmetase in vivo für verbesserte wirksamkeit |
| US20080026444A1 (en) * | 2003-12-24 | 2008-01-31 | Shionogi & Co., Ltd. | Process For Producing Protein-Polymer Complex |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| BRPI1014528A2 (pt) * | 2009-03-18 | 2016-04-05 | Olatec Ind Llc | compostos para tratamento de inflamação e dor |
| EP4062928A3 (de) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotische phenylalanin-ammoniak-lyasen und ihre verwendung zur behandlung von phenylketonurie und hyperphenylalaninämie |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
| US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
| CN107115533A (zh) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
| WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
| JP7176921B2 (ja) | 2017-10-19 | 2022-11-22 | アンチキャンサー インコーポレーテッド | 癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤 |
| CN114681598A (zh) * | 2020-12-30 | 2022-07-01 | 广州华津医药科技有限公司 | 甲硫氨酸酶在制备抗肿瘤的铁死亡诱导剂药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4298590A (en) * | 1975-02-25 | 1981-11-03 | Samuel Bogoch | Detection of malignant tumor cells |
| JPS5313703B2 (de) * | 1974-03-04 | 1978-05-12 | ||
| JPS5352682A (en) * | 1976-10-22 | 1978-05-13 | Mitsui Toatsu Chem Inc | Purification of l-methionase |
| JPS5452033A (en) * | 1977-09-29 | 1979-04-24 | Ajinomoto Co Inc | Preparation of selenoamino acid |
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| JP2557053B2 (ja) * | 1984-12-21 | 1996-11-27 | バイオジェン インコーポレイテッド | 腫瘍壊死因子の精製、製造および使用法 |
| JPH0797997B2 (ja) * | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
-
1993
- 1993-11-19 EP EP02076487A patent/EP1287830B1/de not_active Expired - Lifetime
- 1993-11-19 AU AU56154/94A patent/AU687768B2/en not_active Ceased
- 1993-11-19 CA CA002149776A patent/CA2149776C/en not_active Expired - Fee Related
- 1993-11-19 EP EP94901634A patent/EP0668933B1/de not_active Expired - Lifetime
- 1993-11-19 DK DK94901634T patent/DK0668933T3/da active
- 1993-11-19 US US08/424,300 patent/US5690929A/en not_active Expired - Lifetime
- 1993-11-19 DE DE69332357T patent/DE69332357T2/de not_active Expired - Lifetime
- 1993-11-19 DE DE69334292T patent/DE69334292D1/de not_active Expired - Lifetime
- 1993-11-19 AT AT94901634T patent/ATE225403T1/de not_active IP Right Cessation
- 1993-11-19 ES ES94901634T patent/ES2184756T3/es not_active Expired - Lifetime
- 1993-11-19 AT AT02076487T patent/ATE440615T1/de not_active IP Right Cessation
- 1993-11-19 WO PCT/US1993/011311 patent/WO1994011535A1/en active IP Right Grant
- 1993-11-19 JP JP6512514A patent/JP2930723B2/ja not_active Expired - Lifetime
- 1993-11-19 PT PT94901634T patent/PT668933E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0668933B1 (de) | 2002-10-02 |
| ATE225403T1 (de) | 2002-10-15 |
| CA2149776C (en) | 2008-01-29 |
| DK0668933T3 (da) | 2003-02-10 |
| AU687768B2 (en) | 1998-03-05 |
| EP1287830B1 (de) | 2009-08-26 |
| EP1287830A1 (de) | 2003-03-05 |
| US5690929A (en) | 1997-11-25 |
| DE69332357D1 (de) | 2002-11-07 |
| EP0668933A4 (de) | 1997-05-21 |
| JP2930723B2 (ja) | 1999-08-03 |
| EP0668933A1 (de) | 1995-08-30 |
| JPH08507287A (ja) | 1996-08-06 |
| DE69332357T2 (de) | 2003-06-18 |
| CA2149776A1 (en) | 1994-05-26 |
| AU5615494A (en) | 1994-06-08 |
| ES2184756T3 (es) | 2003-04-16 |
| WO1994011535A1 (en) | 1994-05-26 |
| DE69334292D1 (de) | 2009-10-08 |
| PT668933E (pt) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE225403T1 (de) | Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie | |
| ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
| MX9302906A (es) | Derivados de mercaptoacetilamida novedosos utiles como inhibidores de la encefalinasa. | |
| DK0971713T3 (da) | Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser | |
| ES522085A0 (es) | Procedimiento para producir t-p-a humano activador de plasminogeno. | |
| IT1094660B (it) | Procedimento per la concentrazione di soluzioni con contemporaneo indurimento | |
| DE69317764T2 (de) | Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung | |
| ATE245646T1 (de) | Therapeutische nukleoside | |
| EA200200616A1 (ru) | Химические производные и их применение в качестве антителомеразного агента | |
| IT7868994A0 (it) | Suola di smorzamento per il sopporto elastico della massicciata portante l armamento di binari | |
| ATE128128T1 (de) | Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one. | |
| DE60013486D1 (de) | Verbindungen | |
| EA200200502A1 (ru) | Способ введения ингибитора фосфодиэстеразы 4 | |
| ES2061447T3 (es) | Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas. | |
| DE69326474D1 (de) | Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren | |
| ATE147746T1 (de) | Derivate von fluorphosphonat-nukleotiden | |
| DE3462895D1 (de) | (1h-tetrazol-5-yl)-2(1h)-quinolinones | |
| DK415789A (da) | Tetracykliske antidepressive midler | |
| SE8103580L (sv) | N?726-substituerade adenosiner | |
| DK24687A (da) | 3-alkoxyflavonderivater samt antiviralt virksomme terapeutiske midler indeholdende disse | |
| AT334569B (de) | Befestigung von fuhrungsschienen an schubladen | |
| AR241215A1 (es) | Composiciones herbicidas. | |
| DK0458537T3 (da) | Anvendelse af en terapeutisk forbindelse til behandling af bronkitis | |
| ATE36718T1 (de) | Glykosaminoglykane verwendbar in kosmetologie. | |
| DK301489D0 (da) | Cgrp til anvendelse til forbedring cerebral blodtilfoersel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |